EP0671951A1 - Anticorps humanises reagissant avec l-selectine - Google Patents

Anticorps humanises reagissant avec l-selectine

Info

Publication number
EP0671951A1
EP0671951A1 EP94903357A EP94903357A EP0671951A1 EP 0671951 A1 EP0671951 A1 EP 0671951A1 EP 94903357 A EP94903357 A EP 94903357A EP 94903357 A EP94903357 A EP 94903357A EP 0671951 A1 EP0671951 A1 EP 0671951A1
Authority
EP
European Patent Office
Prior art keywords
immunoglobulin
humanized
human
light chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94903357A
Other languages
German (de)
English (en)
Other versions
EP0671951A4 (fr
Inventor
Man Sung Co
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of EP0671951A1 publication Critical patent/EP0671951A1/fr
Publication of EP0671951A4 publication Critical patent/EP0671951A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Des immunoglobulines humanisées, réagissant spécifiquement avec L-sélectine sont préparées au moyen de techniques de recombinaison d'ADN et sont utilisées pour traiter, notamment, des troubles inflammatoires.
EP94903357A 1992-12-01 1993-11-30 Anticorps humanises reagissant avec l-selectine. Withdrawn EP0671951A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98394692A 1992-12-01 1992-12-01
US983946 1992-12-01
PCT/US1993/011612 WO1994012215A1 (fr) 1992-12-01 1993-11-30 Anticorps humanises reagissant avec l-selectine

Publications (2)

Publication Number Publication Date
EP0671951A1 true EP0671951A1 (fr) 1995-09-20
EP0671951A4 EP0671951A4 (fr) 1997-05-21

Family

ID=25530200

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94903357A Withdrawn EP0671951A4 (fr) 1992-12-01 1993-11-30 Anticorps humanises reagissant avec l-selectine.

Country Status (12)

Country Link
EP (1) EP0671951A4 (fr)
JP (1) JPH08503617A (fr)
KR (1) KR100371784B1 (fr)
AU (1) AU689090B2 (fr)
CA (1) CA2149025A1 (fr)
CZ (1) CZ140195A3 (fr)
FI (1) FI952658A0 (fr)
HU (1) HUT71790A (fr)
NO (1) NO952160L (fr)
PL (1) PL309249A1 (fr)
RU (1) RU2151612C1 (fr)
WO (1) WO1994012215A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
WO1996040942A1 (fr) * 1995-06-07 1996-12-19 Cytel Corporation Anticorps humanises anti-e-selectine
AU746888B2 (en) * 1995-08-17 2002-05-02 Protein Design Labs, Inc. Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
CZ45498A3 (cs) * 1995-08-17 1999-01-13 Protein Design Labs, Inc. Použití antiselektinových protilátek pro výrobu farmaceutických kompozic určených pro prevenci mnohačetného selhání orgánů v důsledku vícečetného úrazu a pro prevenci akutního poškození orgánů po aplikaci mimotělního krevního objehu
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
ATE358492T1 (de) * 1996-09-27 2007-04-15 Univ Columbia Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
WO1999043353A2 (fr) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Therapie combinee par anti-selectine et immunodepresseur
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
EP3689912A1 (fr) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
MX2010006097A (es) 2007-12-05 2010-08-04 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para tratar el prurito.
RU2531521C2 (ru) 2007-12-05 2014-10-20 Чугаи Сейяку Кабусики Кайся Антитело против nr10 и его применение
EP4238993A3 (fr) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène capable de se lier à deux ou plusieurs molécules d'antigène de manière répétée
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
CA2806233C (fr) * 2010-07-26 2021-12-07 Trianni, Inc. Animaux transgeniques et methodes d'utilisation
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
CA2822610C (fr) * 2010-12-21 2019-09-03 Selexys Pharmaceuticals Corporation Utilisation d'anticorps anti-p-selectine
DK2550363T3 (en) 2011-02-25 2015-03-23 Regeneron Pharma ADAM6 mice
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
MX356429B (es) 2011-12-20 2018-05-29 Regeneron Pharma Ratones con cadena ligera humanizada.
LT3597037T (lt) 2012-06-12 2021-06-10 Regeneron Pharmaceuticals, Inc. Humanizuoti gyvūnai, išskyrus žmones, su apribotu imunoglobulino sunkiosios grandinės lokusu
JP2017510273A (ja) 2014-03-21 2017-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 異なる結合特性を示すｖｌ抗原結合タンパク質
KR20210088756A (ko) 2014-03-21 2021-07-14 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
TW202128222A (zh) 2019-11-20 2021-08-01 日商中外製藥股份有限公司 含有抗體之製劑

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011018A1 (fr) * 1990-12-19 1992-07-09 Protein Design Labs, Inc. Immunoglobulines humanisees ameliorees

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011018A1 (fr) * 1990-12-19 1992-07-09 Protein Design Labs, Inc. Immunoglobulines humanisees ameliorees

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Etzioni A. et al: (1992) New Engl. J. Med. 327:1789-1792 *
Fischer A.; Lisowska-Grospierre B.: (1998) Immunodef. Rev. 1:39-54 *
Kansas G.S.: (1996) Blood 88: 3259-3287 *
See also references of WO9412215A1 *
Simpson P.J. et al: (1988) J. Clin. Invest. 81:624-629 *

Also Published As

Publication number Publication date
CA2149025A1 (fr) 1994-06-09
WO1994012215A1 (fr) 1994-06-09
AU5732794A (en) 1994-06-22
JPH08503617A (ja) 1996-04-23
FI952658A (fi) 1995-05-31
NO952160D0 (no) 1995-05-31
KR100371784B1 (ko) 2003-07-22
RU2151612C1 (ru) 2000-06-27
HUT71790A (en) 1996-02-28
HU9501564D0 (en) 1995-07-28
AU689090B2 (en) 1998-03-26
PL309249A1 (en) 1995-10-02
CZ140195A3 (en) 1996-06-12
FI952658A0 (fi) 1995-05-31
NO952160L (no) 1995-07-31
EP0671951A4 (fr) 1997-05-21

Similar Documents

Publication Publication Date Title
AU689090B2 (en) Humanized antibodies reactive with L-selectin
US6210671B1 (en) Humanized antibodies reactive with L-selectin
US6210670B1 (en) Cross-reacting monoclonal antibodies specific for E-selectin and P-selectin
EP0566647B1 (fr) Immunoglobulines humanisees ameliorees
CA2328851C (fr) Immunoglobulines humaines; leurs productions et utilisations
EP0753065B1 (fr) Anticorps contre la selectine e
AU3544589A (en) Il-2 receptor-specific chimeric antibodies
WO1994012214A1 (fr) Anticorps humanises reagissant avec la cd-18
US20030064068A1 (en) Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody
EP0606391B1 (fr) Inhibition du retrecissement vasculaire par l'utilisation d'anticorps anti-padgem
WO1995015181A1 (fr) Therapie de reperfusin comprenant l'utilisation d'anticorps diriges contre la l-selectine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950630

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970404

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTEIN DESIGN LABS, INC.

17Q First examination report despatched

Effective date: 20000407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041126